Relay Therapeutics (RLAY) Operating Margin (2021 - 2026)
Relay Therapeutics (RLAY) posted quarterly Operating Margin of 2619.67% for Q1 2026, down 151446.0% year-over-year from N/an in Q1 2025, and down 202.45% quarter-over-quarter from 866.14% in Q4 2025.
Powered by 
Analysis
Relay Therapeutics (RLAY) Operating Margin (2021 - 2026) Analysis & Trends
Relay Therapeutics (RLAY) has reported Operating Margin for 6 consecutive years, with 2619.67% the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Margin fell 151446.0% year-over-year to 2619.67%; the TTM figure through Mar 2026 stood at 2776.6% (up 200233.0% YoY), while the FY2025 annual figure was 1971.59%, up 175048.0% from the prior year.
- Operating Margin declined to 2619.67% in Q1 2026 per RLAY's latest filing, from 866.14% in the prior quarter.
- Across five years, Operating Margin topped out at 9219600.0% in Q4 2023 and bottomed at 89117.65% in Q2 2023.
- Historically, Operating Margin has averaged 690655.84% across 5 years, with a median of 11351.11% in 2025.
- On a YoY basis, Operating Margin climbed as much as 924839486 bps in 2023 and fell as far as 6779956 bps in 2023.
- Relay Therapeutics' Operating Margin stood at 28794.86% in 2022, then jumped by 32118 bps to 9219600.0% in 2023, then sank by 100 bps to 903.0% in 2024, then gained by 4 bps to 866.14% in 2025, then slumped by 202 bps to 2619.67% in 2026.
- Business Quant data shows RLAY's Operating Margin at 2619.67% in Q1 2026, 866.14% in Q4 2025, and 11351.11% in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -562.07% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 19.06% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 17.93% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 19.75% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.36% |
| 10 | Relay Therapeutics | 3.87 Bn | 3.87 Bn | - | -25,949.71% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -25,949.71% |
| Mar 31, 2026 | -2,619.67% |
| Dec 31, 2025 | -866.14% |
| Jun 30, 2025 | -11,351.11% |
| Mar 31, 2025 | -1,105.21% |
| Mar 31, 2024 | -903.00% |
| Dec 31, 2023 | 9,219,600.00% |
| Sep 30, 2023 | -291.95% |
| Jun 30, 2023 | -89,117.65% |
| Mar 31, 2023 | -44,768.58% |
| Dec 31, 2022 | -28,794.86% |
| Sep 30, 2022 | -24,968.60% |
| Jun 30, 2022 | -21,318.08% |
| Mar 31, 2022 | -14,969.21% |
| Dec 31, 2021 | -11,944.09% |
| Sep 30, 2021 | -9,157.66% |
| Jun 30, 2021 | -22,936.02% |
| Mar 31, 2021 | -4,454.31% |